Literature DB >> 16773689

Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.

Koji Ukai1, Masatoshi Ishigami, Kentaro Yoshioka, Naoto Kawabe, Yoshiaki Katano, Kazuhiko Hayashi, Takashi Honda, Motoyoshi Yano, Hidemi Goto.   

Abstract

AIM: To study the amino acid substitutions in the carboxy (C)-terminal part of E2 protein and in the interferon (IFN) sensitivity determining region (ISDR) and their correlation with response to IFN and viral load in 85 hepatitis C virus (HCV)-1b-infected patients treated with IFN.
METHODS: The C-terminal part of E2 (codons 617-711) including PKR/eIF2alpha phosphorylation homology domain (PePHD) and ISDR was sequenced in 85 HCV-1b-infected patients treated by IFN monotherapy.
RESULTS: The amino acid substitutions in PePHD detected only in 4 of 85 patients were not correlated either with response to IFN or with viral load. The presence of substitutions in a N-terminal variable region (codons 617-641) in the C-terminal part of E2 was significantly correlated with both small viral load (33.9% vs 13.8%, P = 0.0394) and sustained response to IFN (25.0% vs 6.9%, P = 0.0429). Four or more substitutions in ISDR were significantly correlated with both small viral load (78.6% vs 16.2%, P < 0.0001) and sustained response to IFN (85.7% vs 2.9%, P < 0.0001). In multivariate analysis, ISDR in nonstructural (NS) 5A (OR = 0.39, P < 0.0001) and N-terminal variable region (OR = 0.51, P = 0.039) was selected as the independent predictors for small viral load, and ISDR (OR = 39.0, P < 0.0001) was selected as the only independent predictor for sustained response.
CONCLUSION: The N-terminal variable region in the C-terminal part of E2 correlates with both response to IFN monotherapy and viral load and is one of the factors independently associated with a small viral load.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773689      PMCID: PMC4087465          DOI: 10.3748/wjg.v12.i23.3722

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

Authors:  S Brillanti; J Garson; M Foli; K Whitby; R Deaville; C Masci; M Miglioli; L Barbara
Journal:  Gastroenterology       Date:  1994-09       Impact factor: 22.682

3.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

4.  Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083

5.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

6.  Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

Authors:  P Simmonds; F McOmish; P L Yap; S W Chan; C K Lin; G Dusheiko; A A Saeed; E C Holmes
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

7.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

8.  Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources.

Authors:  H Okamoto; Y Sugiyama; S Okada; K Kurai; Y Akahane; Y Sugai; T Tanaka; K Sato; F Tsuda; Y Miyakawa
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

9.  Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.

Authors:  M J Gale; M J Korth; N M Tang; S L Tan; D A Hopkins; T E Dever; S J Polyak; D R Gretch; M G Katze
Journal:  Virology       Date:  1997-04-14       Impact factor: 3.616

10.  Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells.

Authors:  S Maekawa; N Enomoto; N Sakamoto; M Kurosaki; E Ueda; T Kohashi; H Watanabe; C-H Chen; T Yamashiro; Y Tanabe; N Kanazawa; M Nakagawa; C Sato; M Watanabe
Journal:  J Viral Hepat       Date:  2004-09       Impact factor: 3.728

View more
  5 in total

1.  Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein.

Authors:  Ijaz Ali; Sanaullah Khan; Sobia Attaullah; Shahid Niaz Khan; Jabbar Khan; Sami Siraj; Aqib Iqbal; Zahoor A Swati; Muhammad Idrees
Journal:  Virol J       Date:  2011-05-25       Impact factor: 4.099

2.  A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.

Authors:  Alicia Amadoz; Fernando González-Candelas
Journal:  Evol Bioinform Online       Date:  2015-02-23       Impact factor: 1.625

Review 3.  Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design.

Authors:  Alexander W Tarr; Tanvi Khera; Kathrin Hueging; Julie Sheldon; Eike Steinmann; Thomas Pietschmann; Richard J P Brown
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

4.  Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Authors:  P Muñoz de Rueda; J Casado; R Patón; D Quintero; A Palacios; A Gila; R Quiles; J León; A Ruiz-Extremera; J Salmerón
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

Review 5.  The role of HCV proteins on treatment outcomes.

Authors:  Kattareeya Kumthip; Niwat Maneekarn
Journal:  Virol J       Date:  2015-12-15       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.